definiens: shall mean finished pharmaceutically formulated products containing ( 5 - Methyl-2 - oxo - I,3 - dioxolen-4 - yl)methyl 4- ( l - hydroxy - l - methylethyl)-2 - propyl - l-[[2 ' - ( 1 H - tetrazol-5 - yl)biphenyl-4 - yl ] methyl ] imidazole-5 - carboxylate, known generically as olmesartan medoxomil . In addition, shall include finished pharmaceutically formulated products that are combinations of olmesartan medoxomil and hydrochlorothiazide ( sometimes referred to hereinafter separately as a ) . and shall not include ophthalmic formulations . [COMPANY] shall provide Forest with notice of its intention to develop and market in the -4 - 199902 Territory any product(s ) which are i ) salts or metabolites of olmesartan medoxomil or iil combinations of olmesartan and any other active ingredient . [COMPANY] will negotiate in good faith the tenns and conditions for co - promotion of such product(s ) in the Territory by Forest if Forest requests such co - promotion and in the case of ii ) above, such other active ingredient is not subject to an exclusive marketing agreement between [COMPANY] and a third party . The marketing of any such other products in the Territory shall be subject to the provisions of Section 9.1